42.
Gastroenterol 2005;100:2100e15.
43.
randomized trial of antioxidant supplements and anti-helicobacter pylori therapy.
J Natl Cancer Inst 2000;92:1881e8.
44.
intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication.
Gut 2004;53:1244e9.
45.
gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA
2004;291:187e94.
46.
after Helicobacter pylori eradication: a meta-analysis. Digestion 2011;83:253e60.
47.
eradication of Helicobacter pylori. Lancet 1993;342:575e7.
48.
Chen LT, Lin JT, Tai JJ, et al. Long-term results of anti-Helicobacter pylori therapy
2005;97:1345e53.
49.
Stathis A, Chini C, Bertoni F, et al. Long-term outcome following Helicobacter pylori
zone B-cell lymphoma of MALT type. Ann Oncol 2009;20:1086e93.
50.
51.
Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011;60:747e58.
52.
Qu XH, Huang XL, Xiong P, et al. Does Helicobacter pylori infection play a role in
53.
review and meta-analysis. Helicobacter 2008;13:323e40.
54.
55.
infection: a systematic review. Haematologica 2009;94:850e6.
56.
purpura. Haematologica 2009;94:759e62.
57.
Palm F, Urbanek C, Grau A. Infection, its treatment and the risk for stroke. Curr
58.
in a premonitory state for idiopathic parkinsonism and of gastrointestinal infection in
established disease. Gut Pathog 2009;1:20.
59.
beneficial in the management of Alzheimer’s disease. J Neurol 2009;256:758e67.
60.
Franceschi F, Navarese EP, Mollo R, et al. Helicobacter pylori and atherosclerosis.
61.
useful for clinical practice? Int J Cardiol 2009;135:e76e7.
62.
Ayada K, Yokota K, Kobayashi K, et al. Chronic infections and atherosclerosis. Clin
63.
coronary instability: insight from a clinico-pathological study and a meta-analysis of
4241 cases. Atherosclerosis 2009;202:535e42.
64.
allergy. Arch Intern Med 2007;167:821e7.
65.
adults. Int J Epidemiol 2009;38:419e26.
66.
Ioannou GN, Weiss NS, Kearney DJ. Is Helicobacter pylori seropositivity related to
67.
impaired drug absorption. Aliment Pharmacol Ther 2009;29:379e86.
68.
Bugdaci MS, Zuhur SS, Sokmen M, et al. The role of Helicobacter pylori in patients
despite treatment with high doses of thyroxine. Helicobacter 2011;16:124e30.
69.
Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and
2006;66:1824e9.
70.
71.
gene polymorphisms. Gastroenterology 2008;135:91e9.
72.
Schmidt H, Ha D, Tayler E, et al. Variation in human genetic polymorphisms, their
J Gastroenterol Hepatol 2011;26:1725e32.
73.
Gao L, Nieters A, Brenner H. Cell proliferation-related genetic polymorphisms and
2009;12:1658e67.
74.
Snaith A, El-Omar E. Helicobacter pylori: host genetics and disease outcomes.
75.
1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma.
J Natl Cancer Inst 2002;94:1680e7.
76.
2004;20:1001e17.
77.
Gastroenterol 2006;101:1921e30.
78.
2009;44:713e16.
79.
therapy. Jpn J Infect Dis 2009;62:225e7.
80.
Calvet X, Lario S, Ramirez-Lazaro MJ, et al. Accuracy of monoclonal stool tests for
2010;15:201e5.
81.
pylori in stool from children. Eur J Clin Microbiol Infect Dis 2007;26:475e80.
82.
Study Group. Eur J Clin Microbiol Infect Dis 1995;14:428e33.
83.
Fauchere RA, Charlier-Bret N, Courillon-Mallet A, et al. Evaluation comparative de
Helicobacters (GEFH). Feuillet de Biologie 2011;298:25e32.
84.
2001;121:784e91.
85.
Lehours P, Ruskone-Fourmestraux A, Lavergne A, et al. Which test to use to
detect Helicobacter pylori infection in patients with low-grade gastric mucosa-
associated lymphoid tissue lymphoma? Am J Gastroenterol 2003;98:291e5.
86.
Kokkola A, Rautelin H, Puolakkainen P, et al. Positive result by serology indicates
active Helicobacter pylori infection in patients with atrophic gastritis. J Clin
Microbiol 1998;36:1808e10.
87.
Miki K, Ichinose M, Ishikawa KB, et al. Clinical application of serum pepsinogen I
and II levels for mass screening to detect gastric cancer. Jpn J Cancer Res
1993;84:1086e90.
88.
Levine A, Shevah O, Shabat-Sehayek V, et al. Masking of 13C urea breath test by
proton pump inhibitors is dependent on type of medication: comparison between
omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther
2004;20:117e22.
89.
Ozturk E, Yesilova Z, Ilgan S, et al. Performance of acidified 14C-urea capsule
breath test during pantoprazole and ranitidine treatment. J Gastroenterol Hepatol
2009;24:1248e51.
90.
Erzin Y, Altun S, Dobrucali A, et al. Evaluation of two enzyme immunoassays for
detecting Helicobacter pylori in stool specimens of dyspeptic patients after
eradication therapy. J Med Microbiol 2005;54:863e6.
91.
Asfeldt AM, Lochen ML, Straume B, et al. Accuracy of a monoclonal antibody-
based stool antigen test in the diagnosis of Helicobacter pylori infection. Scand J
Gastroenterol 2004;39:1073e7.
92.
Graham DY, Opekun AR, Hammoud F, et al. Studies regarding the mechanism of
false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol
2003;98:1005e9.
93.
Shirin H, Levine A, Shevah O, et al. Eradication of Helicobacter pylori can be
accurately confirmed 14 days after termination of triple therapy using a high-dose
citric acid-based 13C urea breath test. Digestion 2005;71:208e12.
94.
Gisbert JP, Pajares JM. 13C-urea breath test in the management of Helicobacter
pylori infection. Dig Liver Dis 2005;37:899e906.
95.
Graham DY, Opekun AR, Jogi M, et al. False negative urea breath tests with
H2-receptor antagonists: interactions between Helicobacter pylori density and pH.
Helicobacter 2004;9:17e27.
96.
Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on
the efficacy of triple and quadruple first-line therapies for Helicobacter pylori.
Aliment Pharmacol Ther 2007;26:343e57.
97.
Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502.
98.
Wenzhen Y, Yumin L, Quanlin G, et al. Is antimicrobial susceptibility testing
necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis
of randomized controlled trials. Intern Med 2010;49:1103e9.
99.
Oleastro M, Menard A, Santos A, et al. Real-time PCR assay for rapid and accurate
detection of point mutations conferring resistance to clarithromycin in Helicobacter
pylori. J Clin Microbiol 2003;41:397e402.
100.
Cambau E, Allerheiligen V, Coulon C, et al. Evaluation of a new test, genotype
HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori.
J Clin Microbiol 2009;47:3600e7.
101.
Glocker E, Kist M. Rapid detection of point mutations in the gyrA gene of
Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence
resonance energy transfer-based real-time PCR approach. J Clin Microbiol
2004;42:2241e6.
102.
Woo HY, Park DI, Park H, et al. Dual-priming oligonucleotide-based multiplex PCR
for the detection of Helicobacter pylori and determination of clarithromycin
resistance with gastric biopsy specimens. Helicobacter 2009;14:22e8.
103.
Vecsei A, Innerhofer A, Binder C, et al. Stool polymerase chain reaction for
Helicobacter pylori detection and clarithromycin susceptibility testing in children.
Clin Gastroenterol Hepatol 2010;8:309e12.
104.
Kawai T, Yamagishi T, Yagi K, et al. Tailored eradication therapy based on fecal
Helicobacter pylori clarithromycin sensitivities. J Gastroenterol Hepatol 2008;23
(Suppl 2):S171e4.
105.
De Francesco V, Zullo A, Ierardi E, et al. Phenotypic and genotypic Helicobacter
pylori clarithromycin resistance and therapeutic outcome: benefits and limits.
J Antimicrob Chemother 2010;65:327e32.
106.
Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial
susceptibility testing. Clin Microbiol Rev 2007;20:280e322.
107.
Glupczynski Y, Broutet N, Cantagrel A, et al. Comparison of the E test and agar
dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J
Clin Microbiol Infect Dis 2002;21:549e52.
108.
Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for
Helicobacter pylori infection: systematic review and meta-analysis of randomized
controlled trials in adults and children. Am J Gastroenterol 2009;104:3069e79.
109.
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing
antibiotic resistance. Gut 2010;59:1143e53.
110.
Gisbert JP, Calvet X, O’Connor A, et al. Sequential therapy for Helicobacter pylori
eradication: a critical review. J Clin Gastroenterol 2010;44:313e25.
111.
Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug
therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med
2007;146:556e63.
112.
Essa AS, Kramer JR, Graham DY, et al. Meta-analysis: four-drug, three-antibiotic,
non-bismuth-containing “concomitant therapy” versus triple therapy for Helicobacter
pylori eradication. Helicobacter 2009;14:109e18.
113.
Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy
for eradication of Helicobater pylori. Aliment Pharmacol Ther 2011;34:604e17.
114.
Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single
capsule of bismuth biskalcitrate, metronidazoleand tetracycline given with
omeprazole versus omeprazole, amoxicillinand clarithromycin for eradication of
Helicobacter pylori in duodenal ulcer patients: a prospective, randomized,
multicenter, North American trial. Am J Gastroenterol 2003;98:562e7.
115.
O’Morain C, Borody T, Farley A, et al. Efficacy and safety of single-triple capsules
of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for
the eradication of Helicobacter pylori: an international multicentre study. Aliment
Pharmacol Ther 2003;17:415e20.
116.
Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with
a capsule containing bismuth subcitrate potassium, metronidazoleand tetracycline
given with omeprazole versus clarithromycin-based triple therapy: a randomised,
open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905e13.
117.
Glupczynski Y, Megraud F, Lopez-Brea M, et al. European multicentre survey of in
vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis
2001;20:820e3.
118.
Megraud F, Coenen S, Versporten A, et al. Surveillance of Helicobacter pylori
resistance to antibiotics in Europe 2008-2009. (in press).
119.
EMEA. Note for guidance on evaluation of medicinal products indicated for
treatment of bacterial infections. European Medicines Evaluation Agency; London,
2004.
120.
Vallve M, Vergara M, Gisbert JP, et al. Single vs. double dose of a proton pump
inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis. Aliment
Pharmacol Ther 2002;16:1149e56.
121.
Padol S, Yuan Y, Thabane M, et al. The effect of CYP2C19 polymorphisms on
H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Am J Gastroenterol 2006;101:1467e75.
122.
Furuta T, Sugimoto M, Shirai N. Effect of MDR1 C3435T polymorphism on cure
rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin
and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of
H. pylori. Aliment Pharmacol Ther 2007;26:693e703.
123.
Villoria A. Acid-related diseases: are higher doses of proton pump inhibitors more
effective in the treatment of Helicobacter pylori infection? Gastroenterol Hepatol
2008;31:546e7.
124.
Calvet X, Garcia N, Lopez T, et al. A meta-analysis of short versus long therapy
with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin
for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000;14:603e9.
125.
Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori
eradication therapy be improved? Can J Gastroenterol 2003;17(Suppl B):36Be40B.
126.
Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-
pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern
Med 2007;147:553e62.
127.
Haydee B, Salvana A, Ang ELR, et al. Duration of proton-pump inhibitor-based triple
therapy for Helicobacter pylori eradication: a meta-analysis. Gastroenterology;138,5,
suppl. 1:S-340.
128.
Gisbert JP, Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and
either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter
pylori. Aliment Pharmacol Ther 2000;14:1319e28.
129.
Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy
versus standard triple first-line therapy for Helicobacter pylori eradication.
Helicobacter 2009;14:97e107.
130.
Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter
pylori eradication. Aliment Pharmacol Ther 2009;29:720e30.
131.
Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with
probiotics on eradication rates and adverse events during Helicobacter pylori
eradication therapy. Aliment Pharmacol Ther 2007;25:155e68.
131a. Sachdeva A, Nagpal J. Effect of fermented milk-based probiotic preparations on H.
pylori eradication: a systematic review and meta-analysis of randomized-controlled
trials. Eur J Gastroenterol Hepatol 2009;1:45e53.
132.
Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of
Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates
and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069e79.
133.
Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter
pylori therapyeresults of an individual data analysis of 2751 patients. Aliment
Pharmacol Ther 2003;17:99e109.
134.
Abdullahi M, Annibale B, Capoccia D, et al. The eradication of Helicobacter pylori is
affected by body mass index (BMI). Obes Surg 2008;18:1450e4.
135.
Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for
Helicobacter pylori eradication. Am J Med 2006;119:217e24.
136.
Rokkas T, Sechopoulos P, Robotis I, et al. Cumulative H. pylori eradication rates in
clinical practice by adopting first and second-line regimens proposed by the
Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol
2009;104:21e5.
137.
Lee JM, Breslin NP, Hyde DK, et al. Treatment options for Helicobacter pylori
infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Aliment Pharmacol Ther 1999;13:489e96.
138.
Gisbert JP, Gisbert JL, Marcos S, et al. Empirical rescue therapy after Helicobacter
pylori treatment failure: a 10-year single-centre study of 500 patients. Aliment
Pharmacol Ther 2008;27:346e54.
139.
Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-
line treatment for Helicobacter pylori infection: effect of treatment duration and
antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38e45.
Gut 2012;61:646e664. doi:10.1136/gutjnl-2012-302084
661
Guidelines